Bacillus calmette-guerin substrain danish 1331 live antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Bacillus calmette-guerin substrain danish 1331 live antigen
- DrugBank Accession Number
- DB12386
- Background
BCG SSI has been used in trials studying Tuberculosis.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- BCG (SSI strain)
- BCG SSI
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Abatacept. Acyclovir The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Altretamine. Amantadine The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Amantadine. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4CGF0IDN3W
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911329
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Not Yet Recruiting Prevention BCG Vaccination Reaction / Tuberculosis (TB) 1 3 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Heterologous Immunity / Immunosenescence / Morbidity / Non-specific Effects of Vaccines / Vaccine Preventable Disease 1 2 Completed Prevention Tuberculosis (TB) 1 1 Completed Prevention Tuberculosis (TB) 1 Not Available Completed Not Available Tuberculosis (TB) 2 Not Available Completed Prevention Tuberculosis (TB) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 20, 2016 22:10 / Updated on June 12, 2020 16:53